今年以来，石药集团药物研发与对外合作动作频频，正在加速转型。近日，石药集团宣布，其同类首创（First-in-class）帕金森病治疗新药ALMB-0166已获NMPA批准，即将在中国开展Ⅱ期临床试验。该药物瞄准帕金森这一未被满足的临床需求，承载着石药在神经领域的期望。01盼新药解围石药集团的成药业务涵盖神经系统、抗肿瘤、抗感染、心血管、呼吸系统、消化代谢等多个板块。其中，神经系统板块凭借恩必普、...
Source Link今年以来，石药集团药物研发与对外合作动作频频，正在加速转型。近日，石药集团宣布，其同类首创（First-in-class）帕金森病治疗新药ALMB-0166已获NMPA批准，即将在中国开展Ⅱ期临床试验。该药物瞄准帕金森这一未被满足的临床需求，承载着石药在神经领域的期望。01盼新药解围石药集团的成药业务涵盖神经系统、抗肿瘤、抗感染、心血管、呼吸系统、消化代谢等多个板块。其中，神经系统板块凭借恩必普、...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.